Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.

Dalton James SurmeierJack T NguyenNicola LanckiCharles S VenutoDavid OakesTanya SimuniRichard K Wyse

Published in: Movement disorders : official journal of the Movement Disorder Society (2021)

These results are consistent with the recent secondary analysis of the STEADY-PD III clinical trial-suggesting that clinically attainable brain exposure to isradipine may slow early-stage PD progression. © 2021 International Parkinson and Movement Disorder Society.

Keyphrases

clinical trial
early stage
phase ii
study protocol
phase iii
open label
randomized controlled trial
resting state
squamous cell carcinoma
functional connectivity
lymph node
rectal cancer